Phase III let-down worries Novartis share price

29 July 2019

Hopes for a possible extra multi-billion dollar revenue stream have been dented by a top-line miss in the Phase III PARAGON-HF trial of heart med Entresto (sacubitril/valsartan).

Swiss pharma giant Novartis (NOVN: VX) already markets Entresto for reduced fraction heart failure, and has been hoping to broaden the label to include the preserved ejection fraction type of heart disease (HFpEF).

An expanded label would increase considerably the target market for the product, given that HFpEF affects 13 million worldwide. There is currently no approved treatment for this form of cardio-vascular disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK